The Brain Metabolic Change in Chronic Cancer Pain Patient: FDG PET Image Study
1 other identifier
observational
120
1 country
1
Brief Summary
Cancer pain deteriorated in quality of life and related with numerous psychosocial problems. Over the one third of cancer patient suffered from moderate to severe cancer pain, even under adequate pain management. The 18F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) images can provide quantitative results in clinical oncology. As a functional neuroimaging, the PET evidently provided anatomical activated regions, size, and spatial extent information. In this study, we use FDG-PET to investigate changes concerning the glucose metabolism in the brain with or without cancer pain. Therefore, we may provide useful information to treatment target in cancer pain patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 3, 2020
CompletedFirst Posted
Study publicly available on registry
February 5, 2020
CompletedStudy Start
First participant enrolled
March 2, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 28, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 29, 2022
CompletedSeptember 21, 2022
January 1, 2022
2.1 years
February 3, 2020
September 19, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Brain metabolism change
The FDG-PET of Standardized uptake values (SUVs) were calculated for each voxel in the reconstructed images to investigate changes concerning the glucose metabolism in the brain with or without cancer pain
12 months
Study Arms (2)
with cancer pain
head and neck and esophageal cancer patients. with cancer pain
without cancer pain
head and neck and esophageal cancer patients. without cancer pain=30
Interventions
Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.
Eligibility Criteria
Sixty patients in each group of head and neck and esophageal cancer patients. Each cancer group include without cancer pain=30, with cancer pain=30.
You may qualify if:
- Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.
- Age \> 20
You may not qualify if:
- Unable to complete questionnaires.
- Prior evidence of brain metastases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Taiwan University Hosipital
Taipei, 100, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 3, 2020
First Posted
February 5, 2020
Study Start
March 2, 2020
Primary Completion
March 28, 2022
Study Completion
December 29, 2022
Last Updated
September 21, 2022
Record last verified: 2022-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL